TY - JOUR AU - Hilberg, F. AU - Roth, G. J. AU - Krssak, M. AU - Kautschitsch, S. AU - Sommergruber, W. AU - Tontsch-Grunt, U. PY - 2008 DA - 2008// TI - BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6307 DO - 10.1158/0008-5472.CAN-07-6307 ID - Hilberg2008 ER - TY - JOUR AU - Richeldi, L. AU - Bois, R. M. AU - Raghu, G. AU - Azuma, A. AU - Brown, K. K. AU - Costabel, U. PY - 2014 DA - 2014// TI - Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1402584 DO - 10.1056/NEJMoa1402584 ID - Richeldi2014 ER - TY - JOUR AU - Richeldi, L. AU - Costabel, U. AU - Selman, M. AU - Kim, D. S. AU - Hansell, D. M. AU - Nicholson, A. G. PY - 2011 DA - 2011// TI - Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103690 DO - 10.1056/NEJMoa1103690 ID - Richeldi2011 ER - TY - JOUR AU - Suissa, S. AU - Ernst, P. PY - 2015 DA - 2015// TI - The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis JO - Thorax VL - 70 UR - https://doi.org/10.1136/thoraxjnl-2014-206598 DO - 10.1136/thoraxjnl-2014-206598 ID - Suissa2015 ER - TY - JOUR AU - Ogura, T. AU - Taniguchi, H. AU - Azuma, A. AU - Inoue, Y. AU - Kondoh, Y. AU - Hasegawa, Y. PY - 2015 DA - 2015// TI - Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis JO - Eur Respir J VL - 45 UR - https://doi.org/10.1183/09031936.00198013 DO - 10.1183/09031936.00198013 ID - Ogura2015 ER - TY - JOUR AU - Shimizu, R. AU - Fujimoto, D. AU - Kato, R. AU - Otoshi, T. AU - Kawamura, T. AU - Tamai, K. PY - 2014 DA - 2014// TI - The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease JO - Cancer Chemother Pharmacol VL - 74 UR - https://doi.org/10.1007/s00280-014-2590-x DO - 10.1007/s00280-014-2590-x ID - Shimizu2014 ER - TY - JOUR AU - Enomoto, Y. AU - Kenmotsu, H. AU - Watanabe, N. AU - Baba, T. AU - Murakami, H. AU - Yoh, K. PY - 2015 DA - 2015// TI - Efficacy and safety of combined carboplatin, paclitaxel, and bevacizumab for patients with advanced non-squamous non-small cell lung cancer with pre-existing interstitial lung disease: a retrospective multi-institutional study JO - Anticancer Res VL - 35 ID - Enomoto2015 ER - TY - JOUR AU - Reck, M. AU - Kaiser, R. AU - Mellemgaard, A. AU - Douillard, J. Y. AU - Orlov, S. AU - Krzakowski, M. PY - 2014 DA - 2014// TI - Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70586-2 DO - 10.1016/S1470-2045(13)70586-2 ID - Reck2014 ER - TY - JOUR AU - Hanna, N. H. AU - Kaiser, R. AU - Sullivan, R. N. PY - 2013 DA - 2013// TI - LUME-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy JO - J Clin Oncol VL - 31 ID - Hanna2013 ER - TY - JOUR AU - Song, J. W. AU - Hong, S. B. AU - Lim, C. M. AU - Koh, Y. AU - Kim, D. S. PY - 2011 DA - 2011// TI - Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome JO - Eur Respir J VL - 37 UR - https://doi.org/10.1183/09031936.00159709 DO - 10.1183/09031936.00159709 ID - Song2011 ER - TY - BOOK AU - Crestani, B. AU - Ogura, T. AU - Pelling, K. PY - 2015 DA - 2015// TI - Interim analysis of nintedanib in an open-label extension of the INPULSIS trials (INPULSIS-ON) ID - Crestani2015 ER -